ISSN 1006-298X      CN 32-1425/R

Chinese Journal of Nephrology, Dialysis & Transplantation ›› 2017, Vol. 26 ›› Issue (3): 229-234.DOI: 10.3969/cndt.j.issn.1006-298X.2017.03.006

• Article • Previous Articles     Next Articles

Predictive value of brachialankle pulse wave velocity for cardiovascular events in  peritoneal dialysis patients

  

  • Online:2017-06-28 Published:2017-06-29

Abstract:

Objective:To evaluate the predictive value of brachialankle pulse wave velocity (baPWV) for major adverse cardiovascular events (MACE) in patients with peritoneal dialysis.
Methodology:A total of one hundred three end stage renal (ESRD) patients with peritoneal dialysis over 3 months were enrolled into this study. Their baseline characteristics, baPWV and other laboratory measurements were collected and analyzed. According to the patients whether or not suffered from MACE, they were divided into two groups: MACE group (n=29) and nonMACE group (n=74).
Results:The patients in MACE group had significantly higher baPWV(1 943±479 cm/s vs 1 542±325 cm/s,P<0001), Ischemia modified albumin(IMA) levels and high sensitivity Creactive protein (hsCRP) and lower 24h urine volume, serum albumin, total creatinine clearance, residual GFR(rGFR). Multivariable logistic regression analysis results showed that baPWV, IMA and hsCRP were independent risk factors for MACE. From ROC (receiver operating characteristic) curve analysis, the optimal cutoff of baPWV to predict MACE was 1 714 cm/s, with a sensitivity of 6897% and a specificity of 8493% [area under the curve, 0787 (95% confidence interval, 0695,0862); Z=5592,P<005.] Then, two groups were devided. 71 patients had normal baPWV (baPWV<1 714 cm/s) and were assigned the normal baPWV group, and the other 32 patients were assigned to high baPWV group (baPWV≥1 714 cm/s) . Survival analysis showed that there were significant difference between two groups in nonMACE survival(Log rank statistic χ2=3307,P<0001).
Conclusion:
BaPWV can be used as a predictor of peritoneal dialysis patients with MACE.